TXG241115P10000
- 0.05
- -0.05-50.00%
10x Genomics Newsroom
Proteintech Genomics Launches the MultiPro Human Discovery Panel: A New Frontier in Single-Cell Multiomics
Looking Into 10x Genomics's Recent Short Interest
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
TD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $21
10x Genomics Delivers 'Single Cell for a Single Cent' With New Chromium Launches
10x Genomics Is Maintained at Overweight by Barclays
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $21
10x Genomics Price Target Lowered to $21 From $24 at Barclays
Trending Stocks in Another Record Week for Wall Street
Single-cell Technologies Research Report 2023-2024 & 2029 10x Genomics, Agilent Technologies, BD, Bio-Rad Laboratories, Danaher, Illumina, Merck, Promega, Qiagen, & Thermo Fisher Scientific - ResearchAndMarkets.com
Temporary Disruption at 10x Genomics: A Buy Rating Amidst Sales Force Realignment and Strong Product Fundamentals
Cathie Wood's ARK Investment Buys 1.15M Shares of 10x Genomics Today
Small U.S. Stocks Close Lower; 10x Genomics Takes Biggest Hit
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Sector Update: Health Care
Stifel Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $25